CHRYSTAL CAPITAL INTRODUCES FAMILY OFFICES AND UHNWI INVESTORS INTO NORTHERN LEAF
Chrystal Capital Partners LLP (“Chrystal”), a Mayfair based corporate finance and investment house, is pleased to announce that it has acted as exclusive financial advisor to Northern Leaf Limited (“Northern Leaf”), a Jersey based medical cannabis cultivator, on its £3m Pre-IPO preference share fundraise.
Chrystal has been involved with the management team at Northern Leaf since its inception in 2019, acting as the exclusive advisor on its £1.9m founders round in 2020, and on the subsequent £14.25m Convertible Loan Note raise in March 2021. Since then, the company has achieved a number of critical milestones:
Awarded the second ever commercial high THC licence behind GW Pharma 22 years prior.
Built out a state of the art 75,000 sq. ft cannabis cultivation, drying and processing facility capable of delivering 9 tonnes of cannabis flower per annum.
Secured multiple exclusive high THC genetics strains which have now been grown across numerous batch cycles proving quality and consistency of flower for the European medical cannabis markets.
Passed final facility inspections by the MHRA, positioning Northern Leaf to be awarded EU GMP accreditation, expected imminently, which will enable sales across Europe and other medically legal jurisdictions globally.
Employed a number of highly experienced industry personnel across the critical areas of cultivation, operations, sales, quality control and regulation.
Appointed market leading advisors across accounting, legal and broking in anticipation of a summer 2023 IPO onto the London Stock Exchange.
“We are delighted to have supported and advised Northern Leaf again on its third financing. Since inception the strategy has always been to build a European leading medical cannabis business to provide critical and much needed medical products to millions of patients across Europe and further afield suffering from a wide variety of ailments. This additional capital raise will allow Northern Leaf to continue on that path to becoming one of the most strategically important assets in Europe whilst providing much needed medical solutions to patients currently lacking high quality EU GMP supply.”
“Chrystal Capital has been a strong supporter and advisor to Northern Leaf, since its inception in 2019, being integral to our growth and market positioning success. We are excited, after years of capital investment, regulatory clearances, and building the right management team, to begin the monetisation phase of this world class European medical cannabis asset.”
About Northern Leaf
Northern Leaf is a medical cannabis cultivator based in Jersey that, in December 2020, was granted the first UK commercial high THC medical cannabis license since UK based GW Pharmaceuticals (NASDAQ:GWPH) in 1998. The Company is leading the development of a new industry for the British Isles, creating centres of excellence, using state-of-the-art tracking systems and robust policies and procedures to ensure the highest levels of quality from seed to sale. With a secure, operational facility already built, Northern Leaf will grow commercial quantities of medical cannabis for the rapidly growing European market, including the key markets of the UK, Germany, and Israel.
For more information about Northern Leaf, please visit https://www.northern-leaf.com/.
About Chrystal Capital Health and Wellness
Within Chrystal Capital Health & Wellness division, we have one of the leading Cannabis Corporate Finance advisory teams in Europe. They have closed 19 cannabis deals in the last six years, raising and advising on over US$475m of transactions in the pharmaceutical, medical, wellness and cannabis sub-sectors across Europe, North America, and Latin America. They are actively advising clients on IPOs, dual-lists, private capital raises and M&A.
For more information about Chrystal Capital please visit https://www.chrystalcapital.com.
For further information please contact:
Kingsley Wilson
Investment Partner
kingsley.wilson@chrystalcapital.com
https://www.chrystalcapital.com